C3 and paroxysmal nocturnal hemoglobinuria: After the recent successful approval of the C3 inhibitor pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria [26], iptacopan, a novel, low molecular weight, orally active, reversible, and selective inhibitor of Factor B (FB) of the complement AP, is currently developed.